Next Article in Journal
Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment
Next Article in Special Issue
Thioredoxin Reductase-1 as a Potential Biomarker in Fibroblast-Associated HCT116 Cancer Cell Progression and Dissemination in a Zebrafish Model
Previous Article in Journal
Targeting FTO Suppresses Pancreatic Carcinogenesis via Regulating Stem Cell Maintenance and EMT Pathway
Previous Article in Special Issue
A GNAS Gene Mutation’s Independent Expression in the Growth of Colorectal Cancer: A Systematic Review and Meta-Analysis
 
 
Article
Peer-Review Record

Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53–Mutated Metastatic Colorectal Cancer

Cancers 2022, 14(23), 5921; https://doi.org/10.3390/cancers14235921
by Sara Lahoz 1,†, Adela Rodríguez 2,†, Laia Fernández 2, Teresa Gorría 2, Reinaldo Moreno 2, Francis Esposito 2, Helena Oliveres 2, Santiago Albiol 2, Tamara Saurí 2, David Pesantez 2, Gisela Riu 3, Miriam Cuatrecasas 1,4, Pedro Jares 4, Leire Pedrosa 2, Estela Pineda 2, Antonio Postigo 5,6, Antoni Castells 1, Aleix Prat 2, Joan Maurel 1,2,* and Jordi Camps 1,7,*
Reviewer 1: Anonymous
Reviewer 2:
Reviewer 3:
Cancers 2022, 14(23), 5921; https://doi.org/10.3390/cancers14235921
Submission received: 7 September 2022 / Revised: 28 October 2022 / Accepted: 21 November 2022 / Published: 30 November 2022
(This article belongs to the Special Issue Biomarker in Metastatic Colorectal Cancer)

Round 1

Reviewer 1 Report

Major points

1) Table 1; Only 30% of patients received antibody combination therapy. This is very different from the current clinical practice.

2) Table 2; Use of antibody is not related to PFS and OS. This is different from published data.

3) Figure 2; The double mut group is small, 17 cases and 16 cases, respectively. Since there is a possibility that there is a correlation between genetic mutations and response to antibody therapy, an increase in the antibody combination therapy population may have a significant impact on the survival curve of the double mut group.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

The article is focused on the results obtained from the molecular testing by targeted gene sequencing of metastatic colorectal cancer patients.

 

The article is interesting, although not easily to be understood from the general audience, in some parts mainly due to the great amount of data presented.

 

Methodology is properly described and DNA quality was assessed by Qubit. I have concerns about grouping rectal cancer with descendent colon and sigma since generally tumors of the rectum have different features. It might be interesting to compare the different molecular profiles according to tumor location.

 

The conclusions are consistent with the evidence and arguments
presented and address the main question of the study.

Figures are of good quality and report all significative data, as well as tables.

 

The reference section is appropriate.

 

The quality of English is fine.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 3 Report

In the manuscript by Lahoz et al. have defined that SMAD4 and FBXW7 mutations can act as negative prognostic markers in TP53-driven colorectal tumors. The author has performed next-generation sequencing in 294-colorectal patient tumor samples. In addition to correlation between SMAD4 and FBXW7 to TP53, the author has further illustrated pathways that are related to SMAD4 and FBXW7 and suggested that these two molecules can be used as biomarkers to predict the prognostic in colorectal cancer patients. The manuscript is well written and well described; the manuscript can be accepted in the present form.

Author Response

We highly appreciate the Reviewer comments and we are very pleased to read that the Reviewer considers that our manuscript can be published in its present form.

Back to TopTop